Drugs / BGB-B2033
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06427941 | Jul 2024 → Mar 2027 expected | gastric cancer, hepatocellular carcinoma, non-small cell squamous lung carcinoma, yolk sac tumor | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07836530 | Oct 2026 → Sep 2029 expected | hepatocellular carcinoma | BeOne Medicines | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-28 | AbClon | Results 차세대 이중항체 ‘AM105’ 핵심기술 일본 특허 획득… 4-1BB 시장 개화 속 글로벌 지재권 확보 abclon.com ↗
진행성 간세포암 환자군에서 확정 객관적 반응률(ORR) 20.3%를 기록했고, 예측 유효용량 투여군에서는 ORR이 28.9%까지 상승했다. |
| 2026-06-01 | BeOne Medicines | Results BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 beonemedicines.com ↗
Potential first-in-class GPC3x4-1BB bispecific demonstrates unprecedented anti-tumor activity in heavily pre-treated HCC patients |
| 2025-12-18 | BeOne Medicines | Regulatory BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma beonemedicines.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-28 | AbClon | 차세대 이중항체 ‘AM105’ 핵심기술 일본 특허 획득… 4-1BB 시장 개화 속 글로벌 지재권 확보 abclon.com ↗ |
| 2026-06-01 | BeOne Medicines | BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 beonemedicines.com ↗ |
| 2025-12-18 | BeOne Medicines | BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma beonemedicines.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-B2033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06427941 ↗ |
| Route | Intravenous | “Receive BGB-B2033 by intravenous infusion” NCT06427941 ↗ |
| Target | GPC3 | “BGB-B2033 is a new investigational drug designed to bind to a protein called glypican-3 (GPC3)” NCT07836530 ↗ |